收藏切换
The discussion on a proposed quality "similarity assessment criteria" of trastuzumab biosimilar
收藏切换
PDF
Jing CUI, Dong-mei HAN, Long-chang XU, Wei WEI*
Acta Pharmaceutica Sinica | 2021, 56(11) : 3190 - 3197
Less
收藏切换
Acta Pharmaceutica Sinica | 2021, 56(11): 3190-3197
New Drug Forum
The discussion on a proposed quality "similarity assessment criteria" of trastuzumab biosimilar
Full
Jing CUI, Dong-mei HAN, Long-chang XU, Wei WEI*
Affiliations
  • Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China
Published: 2021-11-12 doi: 10.16438/j.0513-4870.2021-0998
Outline
收藏切换

In recent years, many biosimilars have been approved marketing authorization in our country. When conducting research and evaluation of biosimilar, the quality similarity between the candidate drugs and the original drugs is the key point of "biosimilar", meanwhile it is the basis for clinical and marketing authorization of biosimilar. However, the industry and regulatory agencies are facing many challenges in establishing quality "similarity assessment criteria", such as: limited batches of original drugs; quality drift caused by manufacture process changes in the life cycle; analytical method of critical quality attributes is different from different manfactures; statistical methods used for establishing assessment criteria are difficult to unify. In the article, the data obtained from 69 lots of chemistry, manufacturing and control (CMC) dossier of trastuzumab originator company and dossiers of 9 biosimilar companies were analyzed. Furthermore, combined with the risk identification of the critical quality attributes of the product, quality "similarity assessment criteria" have been proposed. This standard has been verified by the disclosure of biosimilar quality data, aim to promote the development and evaluation of trastuzumab biosimilar.

trastuzumab  /  biosimilar  /  quality similarity assessment criteria  /  critical quality attributes  /  chemistry, manufacturing and control review
Jing CUI, Dong-mei HAN, Long-chang XU, Wei WEI. The discussion on a proposed quality "similarity assessment criteria" of trastuzumab biosimilar[J]. Acta Pharmaceutica Sinica, 2021 , 56 (11) : 3190 -3197 . DOI: 10.16438/j.0513-4870.2021-0998
Year 2021 volume 56 Issue 11
PDF
194
82
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2021-0998
  • Receive Date:2021-07-06
  • Online Date:2025-12-18
  • Published:2021-11-12
Article Data
Affiliations
History
  • Received:2021-07-06
  • Revised:2021-09-01
Funding
Affiliations
    Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2021-0998
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT